FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed are an isolated RGMa antibody and an antigen-binding fragment thereof. Also, a nucleic acid molecule, an expression vector, a host cell is considered. Also described is a method for producing the antibody or its antigen-binding fragment and a pharmaceutical composition.
EFFECT: present invention can find further application in therapy of neurological or immunological diseases, in particular Alzheimer's disease and multiple sclerosis.
13 cl, 6 dwg, 3 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
| COMPOSITIONS AND METHODS FOR DIAGNOSTICS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITES DEGENERATION | 2013 |
|
RU2644337C2 |
| METHOD OF PREVENTION OR TREATMENT OF PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS IDENTIFIED | 2019 |
|
RU2822199C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| MYL9 ANTIBODY | 2017 |
|
RU2741802C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
| ANTI-Nogo ANTIBODIES ("11C7") AND THEIR APPLICATION IN PHARMACEUTICS | 2003 |
|
RU2350623C2 |
